New study explores immune drug's potential in hard-to-treat colon cancer
NCT ID NCT06830239
First seen Feb 12, 2026 · Last updated Apr 29, 2026 · Updated 12 times
Summary
This study tests an immunotherapy drug called dostarlimab in 10 people with stage III colon cancer that is mismatch repair proficient (pMMR/MSS), a type that usually does not respond well to immunotherapy. Participants receive two doses of the drug before their scheduled surgery. The main goal is not to cure or shrink the tumor, but to study molecular changes in blood and tissue that might predict which patients could benefit from this approach in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER STAGE III are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UZLeuven
RECRUITINGLeuven, 3000, Belgium
Contact
Conditions
Explore the condition pages connected to this study.